3 years ago

XEN‐augmented Baerveldt surgical success rate and comparison with the Ahmed Valve

Filipa Jorge Teixeira, David Cordeiro Sousa, Nuno Martins Machado, Filipa Caiado, Rafael Barão, Paula Sens, Luís Abegão Pinto

Purpose

The Baerveldt‐XEN technique is intended to reduce the risk of early hypotony after Baerveldt implant, while keeping a good long‐term intra‐ocular pressure (IOP) control. The aim of this study is to discuss the surgical success rate of the Baerveldt‐XEN and compare it with the commercially available flow‐restrictor device (Ahmed glaucoma valve – AGV).

Methods

Single‐centre, cohort study. Consecutive glaucoma patients with uncontrolled IOP > 21 mmHg on maximum tolerated medical therapy, and who had an aqueous shunt as the planned surgical procedure. Patients underwent implantation of Baerveldt‐XEN. An age‐, gender‐ and glaucoma aetiology‐matched database of AGV patients was used for comparison. Complete surgical success was defined as a final IOP between 6 and 21 mmHg, and 20% reduction from baseline with no need for IOP‐lowering medication. Qualified success was the same criteria but resorting to medications.

Results

Twenty‐four eyes from 24 subjects with glaucoma were included in this study, 12 patients underwent Baerveldt‐XEN implantation and 12 AGV. Twelve months after the Baerveldt‐XEN implant, the IOP reduced from 33 ± 9 mmHg to 14 ± 3 mmHg (p < 0.001). The qualified and complete success rate was 50% and 25%, respectively. With the AGV, the IOP reduced from 29 ± 7 mmHg to 16 ± 7 mmHg (p = 0.001). The matched AGV group compared to the Baerveldt‐XEN, presented a higher complete success rate (58.3%) and a qualified success rate of 33.3% (p = 0.72). No sight‐threatening complications were recorded in both groups.

Conclusions

The Baerveldt‐XEN disclosed a low complete success rate at 1 year of follow‐up, although with no major safety concerns. While studies with a longer follow‐up are needed to demonstrate the potential advantages and disadvantages of the Baerveldt‐XEN, this technique may be less likely to achieve drop‐free efficacy when compared to other flow‐restrictor strategies.

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.